Device Judgement Recommended

Similar documents
Validation Study Result Form

Device Equivalence Evaluation Form

Device Equivalence Evaluation Form

Validation of the OMRON 705 IT blood pressure measuring device according to the International Protocol of the European Society of Hypertension

Device Equivalence Evaluation Form

Maker Spacelabs Healthcare Manufacturer Spacelabs Healthcare. Brand Spacelabs Model OnTrak

Validation Study Result Form

Device Equivalence Evaluation Form

Declaration of Equivalence Form

Device Equivalence Evaluation Form

a Medical Physics Department, Guy s & St Thomas NHS Foundation Trust and b King s College School of Medicine, St Thomas Campus, London, UK

Device Equivalence Evaluation Form

Validation of the SEJOY BP-1307 upper arm blood pressure monitor for home. blood pressure monitoring according to the European Society of Hypertension

Validation Study Registration Form

Device Equivalence Evaluation Form

1. Department of Gynecology and Obstetrics, St. Joseph's Hospital Berlin Tempelhof, Germany

STATE OF THE ART BP ASSESSMENT

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

DR JIRAR TOPOUCHIAN PROF PAROUNAK ZELVEIAN PROF ROLAND ASMAR. September 8 th, Principal Investigator and Study Chair:

Comparison of the Microlife A6 PC (BP3GU1-8Y) with the Microlife BP3BT0-A and Microlife BP A100 Plus

Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

BackBeat Cardiac Neuromodulation Therapy (CNT) for Immediate, Substantial and Sustained Lowering of Blood Pressure. Daniel Burkhoff MD PhD

Comparison of the Microlife A2 Basic (BP3GQ1-3P) with the Microlife BP3BT0-A and Microlife BP A100 Plus

Methods DEVICES AND TECHNOLOGY

SYNOPSIS. Publications No publications at the time of writing this report.

Epidemiologic Measure of Association

Reference Values and Simplified Methods for Interpretation of Blood Pressure in Children and Adolescents

Appendix. Supplementary figures and tables


a Centre de Médecine Cardiovasculaire, Paris, France, b Lebanese Hospital and Received 7 June 2009 Revised 15 September 2009 Accepted 9 October 2009

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative

ADVANCE post trial ObservatioNal Study

Validation study of the Dinamap ProCare 200 upper arm blood pressure monitor in children and adolescents

and bias, which are known to be present in self-home and in professional office BP measurements taken using the auscultatory technique [7].

Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

BLOOD PRESSURE MEASUREMENT HOME BASED OR OFFICE BP MONITORING WHICH, HOW AND WHEN?

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care

HCHS/SOL Submission Instructions for Manuscripts or Publications

Hypertension JNC 8 (2014)

A GUIDE TO OUR NIBP TECHNOLOGY

Hypertension and the SPRINT Trial: Is Lower Better

Depok-Indonesia STEPS Survey 2003

THE NEW ARMENIAN MEDICAL JOURNAL DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA)

Received 10 April 2008 Revised 23 June 2008 Accepted 24 June 2008

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

KDIGO Controversies Conference on Blood Pressure in CKD

University of Padova, Padua, Italy, and HARVEST Study Group, Italy

Hypertension Guidelines 2017

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

Blood Pressure Measurement Does it matter where you do it or how often?

Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

Blood Pressure Acre Surgery Diviash Thakrar

ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*

ABPM screen 300/400 Risk Assessment

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics

2. Measure a subject's blood pressure and heart rate both at rest and during exercise.

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

The Use of Alternative Therapies to Lower Blood Pressure in Older African Americans

T. Suithichaiyakul Cardiomed Chula

Patient is healthy with no chronic disease or significant risk factors [16%].

Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT

doi: /fampra/cmw053

Optimal blood pressure targets in chronic kidney disease

Antihypertensive Trial Design ALLHAT

The introduction of oscillometric automated blood pressure

Objectives. Describe results and implications of recent landmark hypertension trials

Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou 1,2,3 Author affiliation:

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Home Blood Pressure Log

Seasonal variation in blood pressure and its relationship with outdoor air temperature in 10 diverse regions of China: the China Kadoorie Biobank

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

Critical Review Form Therapy

Research Article Prevalence, Awareness, Treatment, and Control of Hypertension in Romania: Results of the SEPHAR Study

Blood Pressure Measurement in SPRINT

Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients?

Vital Signs. Vital Signs. Pulse. Temperature. Respiration. Blood Pressure

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Implications of Drug-related Increases in Blood Pressure

Individual Study Table Referring to Item of the Submission: Volume: Page:

Systolic Blood Pressure Intervention Trial (SPRINT)

IRBES_R_04320 Generic drug name: Irbesartan + amlodipine Date: Study Code: 31 active centers: 20 in Korea, 7 in India and 4 in Philippines.

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

Clinical Study Synopsis

The role of physical activity in the prevention and management of hypertension and obesity

Using the New Hypertension Guidelines

DEVICES AND TECHNOLOGY

Hypertension targets in the elderly. Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016

Blood Pressure Targets in Diabetes

Design and analysis of clinical trials

Supplementary Online Content

Use and Interpretation of Home Blood Pressure Monitoring

Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.

Masked Hypertension and Aortic Coarctation: Impact on Ventricular Function and Morphology

HYPERTENSION AND HEART FAILURE

Revision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280

Advances in Peritoneal Dialysis, Vol. 34, 2018

Ambulatory BP Monitoring: Getting the Diagnosis of Hypertension Right. Anthony J. Viera, MD, MPH, FAHA Professor and Chair

Special Lecture 10/28/2012

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Transcription:

dabl Educational Trust Validation Checklist Device Judgement Recommended Manufacturer IEM Device Stabil O Graph Category Upper Arm (Self) Mode Oscillometric Protocol Reference BHS + ESH Westhoff TH, Schmidt S, Zidek W, van der Giet M. Validation of the Stabil O Graph blood pressure self measurement device Journal of Human Hypertension 2007;22,233 235,Research Letter Recruitment Screened 112 (BHS), 41 (ESH) Included 85 (BHS), 33 (ESH) Excluded Explained Some Ranges Correct Yes Ages Correct Yes Sexes Correct Yes Description of Methods Good Procedure Description Good Problems Explained Results Description Good Plots Plots are absent from the letter. These were requested and are included below. Result Pass Both BHS and ESH and also on ESH subgroup from BHS sample Signoff Notes Without plots or subsections, the letter format is not an ideal method of prsenting the results but it does benefit from consiseness. Problems with a fall in pressure in the ESH study high range subjects are addressed with a confirmatory analyis using a subset from BHS study subjects. Date 14/5/2008 Plots and were requested from the authors. These and tables from the original manuscript are included below. 2007 dabl Educational Trust., 34 Main Street, Blackrock, Co. Dublin

Tables Table 1A: Number of patients required and number of patients examined in each blood pressure group of the BHS protocol Systolic BP Diastolic BP Minimum Number of Number of (mmhg) (mmhg) number of subjects subjects subjects examined examined required (systolic) (diastolic) < 100 < 60 8 8 10 100-129 60-79 20 26 22 130-160 80-100 20 21 24 161-180 101-110 20 21 20 >180 >110 8 9 9 Table 1B: Grading criteria of the BHS. To obtain a grade, the device must achieve percentages those reported in the table in all the three categories. Grade Percentage of readings with differences between standard and test device of 5 mmhg 10 mmhg 15 mmhg A 60% 85% 95% B 50% 75% 90% C 40% 65% 85% D Worse than C Worse than C Worse than C 17

Table 1C: Results of the BHS validation procedure, n=85 subjects. Numbers in column 1 correspond to number of measurement in the BHS protocol (Device measurements versus preceding and succeding Observer measurements) Mean ± SD of Grade 5 10 15 30 Mean ± SD (mmhg) differences (mmhg) Observer 1 SBP (1 vs 2, 3 vs 4, 5 vs 6) DBP (1 vs 2, 3 vs 4, 5 vs 6) SBP (2 vs 3, 4 vs 5, 6 vs 7) DBP (2 vs 3, 4 vs 5, 6 vs 7) Observer 2 SBP (1 vs 2, 3 vs 4, 5 vs 6) DBP (1 vs 2, 3 vs 4, 5 vs 6) SBP (2 vs 3, 4 vs 5, 6 vs 7) DBP (2 vs 3, 4 vs 5, 6 vs 7) Final grading B 61% 88% 94% 100% 138.4 ± 30.6-3.1 ± 7.2 A 67% 94% 98% 100% 83.9 ± 16.2 0.1 ± 5.8 A 66% 89% 96% 100% 137.2 ± 30.2-1.9 ± 6.6 A 67% 95% 99% 100% 83.5 ± 16.2 0.5 ± 5.6 B 61% 88% 93% 100% 138.5 ± 30.7-3.2 ± 7.3 A 65% 94% 98% 100% 84.0 ± 16.5 0.0 ± 5.8 B 66% 87% 94% 100% 137.2 ± 30.2-1.9 ± 6.6 A 64% 96% 99% 100% 83.5 ± 16.4 0.5 ± 5.8 SBP A 66% 89% 96% 100% 137.2 ± 30.2-1.9 ± 6.6 DBP A 65% 94% 98% 100% 84.0 ± 16.5 0.0 ± 5.8 18

Table 2A: Number of measurements required and achieved for systolic (SBP) and diastolic (DBP) blood pressure falling in specified error-categories according to phase 1 of the ESH protocol (number of subjects n=15, number of measurements n=45). Error category < 5 mmhg < 10 mmhg < 15 mmhg Required One of 25 35 40 Achieved SBP 32 42 45 DBP 34 39 43 Table 2B: Number of measurements required and achieved for systolic (SBP) and diastolic (DBP) blood pressure falling in specified error-categories according to phase 2.1 of the ESH protocol (number of subjects n=33, number of measurements n=99). Error category < 5 mmhg < 10 mmhg < 15 mmhg Required Two of 65 80 95 All of 60 75 80 Achieved SBP 72 92 99 DBP 75 90 97 19

Table 2C: Number of subjects having the ESH-specified fraction of device-observer differences 5 mmhg for systolic (SBP) and diastolic (DBP) blood pressure (number of subjects 33) Subjects with specified fraction of device-observer differences 2/3 < 5 mmhg 0/3 < 5 mmhg Required Both 22 3 Achieved SBP 25 3 DBP 27 1 20

Table 3: Number of subjects obtained for each blood pressure category according to ESH and BHS criteria in the categorization measurement (BPA) and the following validation measurements (BP1 BP7) BPA BP1 BP3 BP5 BP7 ESH Systolic 90-129 mmhg 11 15 14 16 15 130-160 mmhg 11 15 17 15 17 161-180 mmhg 11 3 2 2 1 Diastolic 40-79 mmhg 11 12 13 13 13 80-100 mmhg 11 15 18 16 16 101-130 mmhg 11 6 2 4 4 BHS Systolic <100 mmhg 8 7 7 7 6 100-129 mmhg 26 30 31 32 32 130-160 mmhg 21 23 23 23 25 161-180 mmhg 21 16 17 18 18 >180 mmhg 9 9 7 5 4 Diastolic < 60 mmhg 10 8 7 7 7 60-79 mmhg 22 25 29 26 29 80-100 mmhg 24 32 29 39 36 101-110 mmhg 20 18 17 9 10 >110 mmhg 9 2 3 4 3 21

Figure legends Figure 1: Tukey mean-difference plots (BHS validation process) of systolic (A) and diastolic (B) blood pressure difference of device and observer in 85 subjects (n=255 measurements). Mean difference for systolic blood pressure is -1.9 ± 6.6 mmhg, mean difference for diastolic blood pressure is 0.1 ± 5.8 mmhg. Figure 2: Tukey mean-difference plots (ESH validation process) of systolic (A) and diastolic (B) blood pressure difference of device and observer in 33 subjects (n=99 measurements). Mean device-observer differences were 0.0 ± 5.6 mmhg (systolic) and 1.0 ± 5.7 mmhg (diastolic). 24

Figures Figure 1A 25

Figure 1B 26

Figure 2 Figure 2A Figure 2B 27